ArticleMedicine2026
Association between thymidine kinase 1 and clinicopathological high-risk features in breast cancer.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymidine kinase 1 (TK1) is a cell-cycle-regulated enzyme involved in DNA synthesis and is closely linked to tumor cell proliferation. This study investigated whether serum TK1 concentration is associated with clinicopathological high-risk features in breast cancer (BC) and whether TK1 changes after neoadjuvant chemotherapy (NACT). This retrospective single center cohort included 410 patients with invasive BC. Serum TK1 was analyzed according to age, lymph node metastasis (LNM), histological grade, Ki-67, circulating tumor cell (CTC) status, tumor size, and BC subtype. Subtypes were analyzed as Luminal A, Luminal B, and a human epidermal growth factor receptor 2 (HER2)-positive/triple-negative breast cancer (TNBC) high-risk group (25 HER2-positive and 35 TNBC cases). Multivariable linear regression included age, LNM, histological grade, Ki-67, CTC status, and subtype. Normality, sensitivity, and nonparametric analyses were performed. In the full-cohort, serum TK1 was higher in patients aged <35 years, in patients with LNM, in grade II/III tumors, and in tumors with Ki-67 > 30%. The univariable difference among the 3 subtype groups was not statistically significant (ANOVA P = .239); however, after adjustment, the HER2-positive/TNBC group had higher serum TK1 than Luminal A tumors (B = 0.197, 95% CI 0.103-0.291, P < .001). CTC status was not independently associated with TK1 (B = 0.020, 95% CI -0.081-0.122, P = .693). The full-cohort sensitivity model excluding CTC yielded consistent results. In the NACT subgroup, serum TK1 decreased after treatment overall and in both complete response and partial response subgroups. Serum TK1 was independently associated with younger age, LNM, higher histological grade, Ki-67, and the HER2-positive/TNBC high-risk phenotype. Serum TK1 also decreased after NACT. Because survival, recurrence-free survival, and disease-free survival were not evaluated, these findings support TK1 as a proliferation-related biomarker for risk stratification and treatment response monitoring, but not as definitive evidence of long-term outcome prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.